Venue: Crowne Plaza-Cabana Hotel, 4290 El Camino Real, Palo Alto, CA
The EPPIC annual life science conference combines networking, mentoring, keynote lectures and panel discussions on current topics. The annual conference also focuses on promoting cross border (US-India) collaborations and attracts multiple individuals and organizations interested in leveraging potential synergies. This year’s panels- Research & Development, Clinical Trails, Bio-IT and Mergers & Acquisitions will give attendees a good grasp on the latest trends in industry. The annual conference also hosts two speed networking sessions to promote interaction among attendees. The conference brings budding and seasoned entrepreneurs, senior executives, scientists, venture capitalists and legal experts, together to tell their stories and will attract potential partners, employees and investors.
Registration: Early Bird Registration: $100 (ends on Dec 27th, 11.55 pm)
Advance Registration: $125 (Dec 28 - Jan 7th, 11.55 pm)
On site Registration: $150 (Jan 9th 7.30 am - 2 pm)
Student/Postdoc registration: $50 (ends by Dec 27th, only first 25 will be allowed). A valid ID must be shown. Otherwise, they will be considered as a regular attendee.
Registration fee is waived for Charter Members (please write to "eppicglobal@gamil.com" for charter memberhip benefits) if you are interested to become a Charter Member in 2011 year.
Attendees who plan to register through check option, you must send the check payable to "EPPIC GLOBAL" and mail the check to EPPIC mailing address (EPPIC GLOBAL NETWORK, PMB# 402, 4546 El Camino Real, Suite B-10, Los Altos, CA 94022-1069) no later than Dec 31st, 2010.
Checks received after Dec 31st considered as on-site registration and you will have to pay additional $50 ($150 instead of $100).
No refunds on registration fee. But transferring the registration fee to an another attendee can be considered by only prior written request to "eppicglobal@gmail.com".
Registration fee to EPPIC 2011 Annual Conference includes EPPIC Annual Membership ($35), breakfast, coffee, reception (light refreshments) and access to sponsor information booths etc. Student registration fee does not include Annual membership fee. Please note that registration fee is at substantially discounted price to all attendees due to generous sponsorship from Life Science corporations and 100% volunteer work by organizing committee to reduce overhead costs. Please help us spreading the word on EPPIC 2011 Annual Conference to all Life Science professionals.
Hal Barron, CMO & Executive VP, Global Product Dev., Genentech
It costs over $1.2 billion to develop a drug today. This is driven by increasingly clinical trial costs, failure rates and the time required to conduct these studies. One approach to improving the current model focuses on personalized health care. The purpose of this talk is to discuss specific examples which highlight the value and challenges associated with this strategy.
9.45 – 10.45 am
Panel 1: R&D: BENCH TO BREAKTHROUGH: ACCELERATE INNOVATION VIA PARTNERSHIPS
Moderator:Sara Kenkare-Mitra, Vice President, Development Science, Genentech KT Rao, CSO, Vice President of R&D, Nellix Endovascular Peter Sausen, Global Vice President, Non Clinical Drug Development, Covance Dale Schenk, CSO & Executive Vice President, Elan Pharmaceuticals Florian Schödel, Founder, Philimmune, LLC & former VP, Vaccine Clin Res, Merck Deepak Srivastava, Director, Gladstone Research Institute, UCSF
Partnerships are clearly becoming more and more important to drive innovation in the biotech and pharmaceutical industry. Whether it is early small biotechs that rely on CRO partners for key drug development support or partnerships with academic labs to avail of novel biological insights, these partnerships are serving an important role in the current biotech paradigm. In this panel, we will discuss various partnership models in different domains of the life sciences. Experts from large pharma, biotech, CRO, medical device companies and academia will share their real life experiences and highlight success strategies and challenges.
10.45 – 11.30 am
SESSION 2: Speed Networking-1
An opportunity to meet over 100 attendees by 3 min quick introductions with a group of three attendees and also in a group setting. Please bring ~150 business cards.
11.30 – 12.30 pm
Panel 2: CLINICAL TRAILS: MOLECULES TO MEDICINES: ARE WE GETTING BETTER?
The problem of low NCE productivity continues to bedevil the pharmaceutical industry. This panel will focus on progress in three broad areas aimed at addressing this challenge: Exploratory IND’s or Phase 0 Clinical Trials; Advances in Translational Research or Medicine; Impact of expanding trials globally particularly into Asia. Phase 0 Clinical Trials and Translational Research focus on methodologies to minimize late-stage drug failures and ensure higher probability of success by improving the drug candidate selection process early-on. The global outreach for conducting clinical trials, particularly in Asia has two potential benefits: (1) time and cost savings in the form of faster patient accruals and lower per patient expenses for clinical development in therapeutic areas traditionally identified as being “profitable” for the pharmaceutical industry, and (2) setting up infra-structure, incentives and public-private partnerships for addressing so-called “neglected diseases” in poorer countries.
12.30 – 1.30 pm
Lunch Break:
1.30 – 2.00 pm
KEYNOTE ADDRESS-1: FDA’S FINDINGS FOR BIORESEARCH MONITORING INSPECTIONS, WHAT WE SEE AND WHAT WE WOULD LIKE TO SEE!
Mark Roh, REGIONAL FOOD AND DRUG DIRECTOR, PACIFIC REGION, FDA
New and Abbreviated Human Drug Applications often require inspections of the manufacturing site before the product is approved. Part of that process involves bioresearch monitoring inspections to review the clinical data collected when compared to the clinical data submitted in the application process. Problems discovered during these bioresearch monitoring inspections can result in delayed approval or denial of approval of the application. This presentation will describe many of the objectionable conditions noted during these inspections by FDA between years 2005 and 2010.
2.00 – 2.30 pm
KEYNOTE ADDRESS-2: PARTNERING AND M&A WITH BIG PHARMA: BIOTECH’S BRIDGE OVER TROUBLED WATERS
Barbara Yanni, VICE PRESIDENT & CHIEF LICENSING OFFICER, MERCK
It is a tough financial environment for today's biotechs. Many have chosen to do deals with big pharma as a way to fund further research. These deals range from licenses, partnerships and collaborations to M&A. Since big pharma also needs to mitigate risk, deal terms -- whether licensing or M&A -- are often similar in structure in that they include an upfront payment plus contingent payments based on success. Ms. Yanni will discuss these deal trends, Merck's approach to licensing, and highlight recent case studies.
2.30 – 3.30 pm
PANEL 3: M&A: THE GOOD, BAD & UGLY
Moderator: Ian Edvalson, Partner, Wilson Sonsini Goodrich & Rosati
Bhaskar Chaudhuri, former President, Valeant Pharmaceutical International
John DeYoung, Vice President, Business Development-Oncology, Pfizer
Sunil Patel, Senior Vice President, Oncomed Pharmaceuticals
Stan Yakatan, Co-founder & Chairman, Katan Associates
In 2010, we have seen the stock market recover, but new healthcare IPOs are still scarce. Given the relatively small number of public exits, venture capital investments have shifted focus from early stage investments to later stage. Big pharma and biotechs are also dealing with pipeline challenges, patent expirations and impact from healthcare reform. The appetite to acquire early stage biotech companies outright is lacking, and partnerships are offering smaller upfront payment and insisting on milestones. Our panelists will review the key trends from 2010, and predict what the future holds in 2011 for different stakeholders.
3.30 – 4.00 pm
SESSION 5: Speed Networking-2
Opportunity to meet other attendees
4.00 – 4.30 pm
KEYNOTE ADDRESS-3: TRENDS IN MEDICAL DEVICE PARTNERING
KEYNOTE ADDRESS-4: THE ROAD TO THE $1000 GENOME AND BEYOND!
Kevin Davies, EDITOR, BIO-IT WORLD AND AUTHOR OF $1000 GENOME
In 2007, Jim Watson, the man who co-discovered the double helix, was presented with his personal genome sequence on a portable hard drive, ushering in a new era of personalized genomic medicine. Since then, dozens of named individuals have been sequenced along with nearly 3,000 research samples. The cost of whole-genome sequencing has dropped from $1 million just a few years ago to less than $10,000. Indeed, anyone can get their genome sequenced for less than $20,000 if they have a doctor’s note. Kevin Davies, author of The $1,000 Genome, explores the medical and ethical implications of next-generation sequencing and personal genomics.
In an era of aging product portfolios, escalating costs, dramatic reduction of new drug approvals, complicated and burdensome regulatory pathways, life science companies are faced with increasing challenges in recreating their future through growth and innovation. Companies will need to invest in new R&D operating models that will leverage their scientific and clinical expertise with cutting-edge software platforms. They will need to utilize technology at an unprecedented level across all aspects of their business to achieve significant breakthroughs in efficiency and risk reduction. In this panel experts, who have merged software platforms into the life sciences arena, will talk about their experiences as well as opportunities for more partnerships.
EPPIC 2011 Annual Conference Co-chair, Managing Director, Adjuvant Global Advisors
6.15 – 7.00 pm
Evening Reception: Cocktails and light refreshments
To Volunteer or Sponsor, please contact – Jagath Reddy Junutula (jagathjr@gmail.com), Ravi Kiron (rkiron@adjuvant.com), or the Executive Committee members.
